%0 Journal Article
%T Lack of effect of apolipoprotein C3 polymorphisms on indices of liver steatosis, lipid profile and insulin resistance in obese Southern Europeans
%A Federica Sentinelli
%A Stefano Romeo
%A Cristina Maglio
%A Michela Incani
%A Maria A Burza
%A Francesca Scano
%A Federica Coccia
%A Efisio Cossu
%A Frida Leonetti
%A Marco G Baroni
%J Lipids in Health and Disease
%D 2011
%I BioMed Central
%R 10.1186/1476-511x-10-93
%X To determine if the APOC3 variants alter the susceptibility of obese subjects to develop liver damage, hypertrigliceridaemia, and insulin-resistance.The study was carried out on 585 unrelated obese Italians (median body mass index BMI = 41 kg/m2) who were genotyped for the rs2854116 and rs2854117 variants. All participants underwent oral glucose tolerance tests (OGTT), with measurement of glucose, insulin, lipid parameters. Indices of insulin-resistance (HOMA and ISI) were calculated. Alanine transaminase (ALT) and aspartate transaminase (AST) were used as markers of liver injury.The study subjects were divided into two groups: those homozygous for the wild-type alleles at both SNPs (-482C and -455T alleles) and those who were carriers of at least one variant allele or both (-482T, -455C or both). Also each SNP was analysed independently. No significant differences were found in ALT and AST levels and in the lipid profile between the two groups. Insulin concentrations, glucose tolerance and insulin sensitivity were similar in the two groups.We did not identify any significant association between APOC3 polymorphisms and fatty liver disease, lipids, and insulin-resistance in obese subjects, thus not confirming the suggested role of these APOC3 gene sequence variants.Non-alcoholic fatty liver disease (NAFLD) is a multifactorial disorder arising from the interplay between genetic susceptibility and environmental influences. A large body of evidence shows that NAFLD is highly related to obesity and its metabolic consequences such as insulin resistance and dyslipidaemia [1]. In addition to altering metabolic risk, hepatic steatosis is also associated with significant liver disease in some patients. As many as 10-20% of patients with NAFLD develop steatohepatitis [1] and approximately 5% proceed to liver cirrhosis within 10 years of diagnosis [2].The hallmark of hepatic steatosis is the presence of triglycerides (TGs) stored as large lipid droplets in the cytoplasm of hepa
%K hepatic transaminases
%K NAFLD
%K BMI
%K obesity
%K tryglicerides
%K HDL
%K atherogenic dyslipidemia
%U http://www.lipidworld.com/content/10/1/93